Opinion|Videos|December 25, 2024

PRECISION trial

Key Takeaways

  • Difficult-to-treat hypertension involves uncontrolled blood pressure despite using three or more antihypertensive medications, including a diuretic.
  • It is distinct from resistant hypertension, which is more common and may not include a diuretic in treatment.
SHOW MORE

Panelists discuss how the PRECISION trial evaluated aprocitentan, a dual endothelin receptor antagonist (ERA), in patients with resistant hypertension taking 3 antihypertensive medications including a diuretic.

Video content above is prompted by the following:

The PRECISION trial was a phase 3, multicenter, randomized study of aprocitentan, a dual ERA, in patients with a systolic blood pressure of 140 mm Hg or higher despite taking 3 antihypertensive drugs, including a diuretic.


Latest CME